Prescient Therapeutics CEO James McDonnell talked with Proactive about the company’s strong September quarter performance and ongoing progress in its Phase 2 trial of PTX-100 for cutaneous T-cell lymphoma (CTCL). McDonnell said Prescient ended the quarter with A$12.3 million in cash and has now activated seven clinical sites, with six patients in dosing and additional participants in screening.
He explained that early results from Phase 1b data strongly supported the transition into Phase 2, with a 43% response rate and 100% clinical benefit observed in patients. “No adverse events were associated with PTX-100, so it can’t get much better than that,” McDonnell noted, adding that the duration of response extended to over 12 months.
Prescient is also working toward orphan drug designation in Europe, with several new trial sites expected to open by the end of the year. McDonnell said these developments underline a “clear pathway” for the company’s ongoing clinical work.
For more interviews and company updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications to stay informed about future releases.
#ClinicalTrial #BiotechStocks #OncologyUpdate #TCellLymphoma #CancerTherapy #InvestorNews #ASXStocks #BiotechInvestment